We are live on ! Find out more
JSPR icon

Jasper Therapeutics

69 hedge funds and large institutions have $330M invested in Jasper Therapeutics in 2024 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

215% more call options, than puts

Call options by funds: $3.25M | Put options by funds: $1.03M

55% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 11

44% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 18

13% more funds holding

Funds holding: 6169 (+8)

10.01% more ownership

Funds ownership: 86.51%96.52% (+10%)

13% less capital invested

Capital invested by funds: $380M → $330M (-$50.4M)

17% less funds holding in top 10

Funds holding in top 10: 65 (-1)

Holders
69
Holders Change
+8
Holders Change %
+13.11%
% of All Funds
1%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.07%
New
26
Increased
17
Reduced
11
Closed
18
Calls
$3.25M
Puts
$1.03M
Net Calls
+$2.22M
Net Calls Change
-$1.19M

JSPR Hedge Fund Activity: Q2 2024 in Review

69 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q2 2024, worth a combined $330M — down 13% from $380M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new JSPR positions and 18 closed out — a net gain of 8 holders — while 17 added to existing stakes and 11 trimmed.

The largest buyer was Polar Capital Holdings, opening a new position worth an estimated $13.9M. The largest seller was Octagon Capital Advisors, cutting an estimated $5.12M.

  • 69 institutional investors held Jasper Therapeutics (JSPR) as of Q2 2024, up from 61 in Q1 2024.
  • Funds reported $330M of Jasper Therapeutics stock for Q2 2024, down 13% quarter-over-quarter.
  • 26 funds opened new Jasper Therapeutics positions in Q2 2024 and 18 closed out, a net change of +8 holders.
  • The largest Jasper Therapeutics buyer in Q2 2024 was Polar Capital Holdings, an estimated $13.9M added.
  • The largest Jasper Therapeutics seller in Q2 2024 was Octagon Capital Advisors, an estimated $5.12M sold.

Based on aggregated 13F filings for Q2 2024.